Search results

The study presents a conceptual model of a firm's supply chain agility (FSCA) as a formative construct formed by sensing and responding capabilities. Both construct validity and predictive validity of the model are tested by investigating nuanced effects of FSCA on business performance. The study aims to empirically validate the sensing-responding theoretical framework of Overby et al. (2006) and extend the emergent stream on sensing-responding frameworks for supply chain agility.

Survey research is employed. Data are analysed using partial least squares technique and mediation tests by Hayes PROCESS macro.

FSCA is established as a revised construct formed by the distinct capabilities of sensing and responding. The efficacy of utilizing FSCA as a formative 2nd order construct was established. In addition, FSCA is shown to affect business performance through mediations of cost efficiency and customer effectiveness, establishing its predictive validity.

This study contributes significantly to the literature on supply chain agility in terms of both theory and practice for cultivating supply chain agility. Drawing on resource-based view and resource-advantage theories, as reformulation of supply chain agility as a formative construct of sensing and responding capabilities, this research opens up new lines of inquiry on agility.

The objective of this study is to explore the structural attributes of the pharmaceutical industry before the onset of the COVID-19 pandemic by examining the relationship between inventory and firm performance and developing a taxonomy of pharmaceutical firms based on the earns-turns matrix.

This study examines the inventory–firm performance linkage, considering both total inventory and its discrete inventory components in pharmaceutical firms. In addition, this research develops a new taxonomy of pharmaceutical firms based on the earns-turns matrix. A large panel dataset of firms in the US pharmaceutical industry was collected for the period 2000–2019.

The results reveal that strategic groups identified based on this taxonomy show different levels of profitability and inventory turns in the earns-turns matrix. Most pharmaceutical firms moved from the low-right to the top-left section in the earns-turns matrix, indicating that these firms have generally pursued profitability rather than effective inventory management.

This study explores the structural attributes of the pharmaceutical industry using the earns-turns matrix. This two-dimensional analysis may not, however, capture the full complexity of inventory–firm performance dynamics.

The mapping of strategic groups on the earns-turns matrix provides a useful tool for visual representations of the dynamics of strategic groups in terms of financial performance and inventory management performance. Practitioners can use the earns-turns matrix to benchmark their firm's position against their competitors.

This study broadens the scope of operations management research by introducing the earns-turns matrix as an empirical validation tool for operational and strategic management theories. This study emphasizes the effectiveness of the earns-turns matrix in analyzing strategic groups of pharmaceutical firms.